Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’

BACKGROUND: The magnitude of clinical benefit of solid cancer drugs can be standardly assessed via the Magnitude of Clinical Benefit Scale (MCBS) developed by the European Society for Medical Oncology (ESMO). We applied two ESMO-MCBS versions to the last 12 years of European cancer drug approval and...

Descripción completa

Detalles Bibliográficos
Autores principales: Grössmann, N., Wolf, S., Rothschedl, E., Wild, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182388/
https://www.ncbi.nlm.nih.gov/pubmed/34087744
http://dx.doi.org/10.1016/j.esmoop.2021.100166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182388/
https://www.ncbi.nlm.nih.gov/pubmed/34087744
http://dx.doi.org/10.1016/j.esmoop.2021.100166

Ejemplares similares